RVTY Revvity, Inc. Common Stock
NYSE · Life Sciences Tools & Services · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 11, 2026RVTY Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
RVTY Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| June 4, 2001 | 2-for-1 | Forward |
| May 11, 1992 | 2-for-1 | Forward |
| Feb. 2, 1982 | 2-for-1 | Forward |
| Feb. 4, 1980 | 2-for-1 | Forward |
About Revvity, Inc. Common Stock Company overview from Wikipedia
PerkinElmer, Inc., previously styled Perkin-Elmer, is an American global corporation that was founded in 1937 and originally focused on precision optics. Over the years it went into and out of several different businesses via acquisitions and divestitures; these included defense products, semiconductors, computer systems, and others. By the 21st century, PerkinElmer was focused in the business areas of diagnostics, life science research, food, environmental and industrial testing. Its capabilities include detection, imaging, informatics, and service. It produced analytical instruments, genetic testing and diagnostic tools, medical imaging components, software, instruments, and consumables for multiple end markets. PerkinElmer was part of the S&P 500 Index and operated in 190 countries.
Over its history, PerkinElmer has been split in two twice. In 1999, PerkinElmer merged with EG&G, with the ongoing Analytical Instruments Division of Perkin-Elmer keeping that name, while the life sciences division of the company became the separate PE Corporation. In 2022, a split of PerkinElmer resulted in one part, comprising applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but kept the PerkinElmer name. The other part, comprising life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc.
History
Founding
Richard Perkin was attending the Pratt Institute in Brooklyn to study chemical engineering, but left after a year to try his hand on Wall Street. Still interested in the sciences, he gave public lectures on various topics. Charles Elmer ran a firm that supplied court reporters and was nearing retirement when he attended one of Perkin's lectures on astronomy being held at the Brooklyn Institute of Arts and Sciences.
The two struck up a friendship over their shared interest in astronomy, and eventually came up with the idea of starting a firm to produce precision optics. Perkin raised US$15,000 from his relatives, while Elmer added US$5,000, and the firm was initially set up as a partnership on 19 April 1937. Initially, they worked from a small office in Manhattan, but soon opened a production facility in Jersey City. They incorporated the growing firm on 13 December 1939. A further move to Glenbrook in Connecticut in 1941 was quickly followed by another move to Norwalk, Connecticut, where the company remained until 2000. The opening of World War II led to significant expansion as the company produced optics for range finders, bombsights, and reconnaissance systems. This work led to the U.S. Navy awarding them the first "E" for Excellence award in 1942.
Perkin-Elmer retained a strong presence in the military field through the 1960s and at the same time was significantly involved with OAO-3 a 36-inch Ultra Violet Space Telescope and Skylab. They contributed to the Apollo program by development of a CO2 sensor that was, however, supplanted by a Coleman Instruments product. PE at the Norwalk plant also conducted one of the first researches into computer-digital enhancement of scanned images, contracted for application to the Corona spy satellite, film imagery. They were a primary supplier of the optical systems used in many reconnaissance platforms, first in aircraft and high-altitude balloons, and then in reconnaissance satellites. A significant advance was 1955's Transverse Panoramic Camera, which took images on 12 by 14 ft (3.7 by 4.3 m) wide frames that provided single-frame images from horizon to horizon from an aircraft flying at 40,000 ft altitude. Such systems remained a major part of the company's income, capped by the installation of laser retroreflectors on the Moon as part of the Apollo 11 mission.
Elmer died at age 83 in 1954, and the company began trading shares over the counter. The company was listed on the New York Stock Exchange on 13 December 1960. Perkin remained as president and CEO until June 1961, when Robert Lewis, previously of Argus Camera and Sylvania Electric Products, took over these roles. Perkin remained the chairman of the board until his death in 1969.
Semiconductor manufacturing
In 1967, the U.S. Air Force asked Perkin-Elmer to produce an all-optical "masking" system for semiconductor fabrication. Previous systems used a pattern, the "mask", which was pressed onto the surface of the silicon wafer as part of the photolithography process. Small bits of dirt or photoresist would stick the mask and ruin the patterning for subsequent chips, and it was not uncommon for the vast majority of the chips from a given wafer to malfunction. The Air Force, which by the late 1960s was highly reliant on integrated circuits, desired a more reliable system.
Perkin-Elmer responded with the Microprojector, which was essentially a large photocopier system. The mask was placed in a holder and never touched the surface of the chip. Instead, the image was projected onto the surface. Making this work required a complex 16-element lens system that focussed a narrow range of wavelengths of light onto the mask. The remainder of the light from the 1,000 watt mercury-vapor lamp was filtered out. PE also developed a micro-densitometer in 1967 that scanned micro-chips for quality control
Harold Hemstreet was convinced that the concept could be simplified, and Abe Offner began the development of a system using mirrors instead of lenses, which did not suffer from the multispectral focussing problems of lenses. The result of this research was the Projection Scanning Aligner, or Micralign, which made chip making an assembly-line task and improved the number of working chips from perhaps 10% to 70% overnight. Chip prices plummeted as a result, with examples like the MOS 6502 selling for about US$20 while the previous generation of designs like the Motorola 6800 sold for around US$250.
The Micralign was so successful that Perkin-Elmer became the largest single vendor in the chip space in three years. In spite of this success, the company was largely a has-been by the 1980s due to their late response to the introduction of the stepping aligner, which allowed a single small mask to be stepped across the wafer, rather than requiring a single large mask covering the entire wafer. The company never regained their lead, and sold the division to The Silicon Valley Group.
Lab equipment
Perkin Elmer was a leading developer and supplier of lab analytic equipment from the 1950's. By the 1960's the Norwalk/Wilton, CT facilities were developing and producing a wide variety of instruments including multi-spectral spectrometers (IR, visible, UV), gas chromatographs, and atomic absorption spectrometers and Raman spectrometers. The plants housed integrated research, engineering, production (optical and electronic) and support facilities. In the early 1990s, partnered with Cetus Corporation (and later Hoffmann-La Roche) to pioneer the polymerase chain reaction (PCR) equipment industry. Analytical-instruments business was also operated from 1954 to 2001 in Germany, by the Bodenseewerk Perkin-Elmer GmbH located in Überlingen at Lake Constance, and England (Perkin Elmer Ltd) at Beaconsfield in Buckinghamshire.
Computer Systems Division
Perkin-Elmer was involved in computer manufacture for a time. The Perkin-Elmer Computer Systems Division was formed through the purchase of Interdata, Inc., an independent computer manufacturer, in 1973–1974 for some US$63 million. This merger made Perkin-Elmer's annual sales rise to over US$200 million. This was also known as Perkin-Elmer's Data Systems Group. The 32-bit computers were very similar to an IBM System/370, but ran the OS/32MT operating system. In 1976, Perkin-Elmer acquired Wangco, a Los Angeles manufacturer of tape drives for $30 million in a stock swap.
The Computer Systems Division had a large presence in Monmouth County, New Jersey, with some 1,700 staff making it one of the county's largest private employers. Its plant in Oceanport had 800 employees alone. By the early-mid-1980s the computing group had sales of $259 million; while profitable, it tended to have reduced visibility within the computing industry due to being owned by a diversified parent.
The Wollongong Group provided the commercial version of the Unix port to the Interdata 7/32 hardware, known as Edition 7 Unix. The port was originally done by the University of Wollongong in New South Wales, Australia, and was the first UNIX port to hardware other than the Digital Equipment Corporation PDP family. By 1982, the Wollongong Group Edition 7 Unix and Programmer's Workbench (PWB) were available on models such as the Perkin-Elmer 3210 and 3240 minicomputers.
In 1985, the computing division of Perkin-Elmer was spun off as Concurrent Computer Corporation, with the goal of giving it and the parallel processing product a clearer identification within the computer industry. At first, the new company was a wholly owned subsidiary of Perkin-Elmer, but with the intentions of putting a minority ownership in the company up for a public stock sale. This was done one in February 1986, with Perkin-Elmer retaining an 82 percent stake in Concurrent. In 1988, there was a merger between Concurrent Computer Corporation and MASSCOMP; as part of the deal, Perkin-Elmer's share in Concurrent was bought out. At that point, Perkin-Elmer said they had culminated their multi-year process of exiting from computer market, allowing them to focus on their primary business segments.
1999
Modern PerkinElmer traces its history back to a merger between divisions of what had been two S&P 500 companies, EG&G Inc. (formerly NYSE: EGG) of Wellesley, Massachusetts and Perkin-Elmer (formerly NYSE: PKN) of Norwalk, Connecticut. On May 28, 1999, the non-government side of EG&G Inc. purchased the Analytical Instruments Division of Perkin-Elmer, its traditional business segment, for US$425 million, also assuming the Perkin-Elmer name and forming the new PerkinElmer company, with new officers and a new board of directors. At the time, EG&G made products for diverse industries including automotive, medical, aerospace and photography.
The old Perkin-Elmer Board of Directors and Officers remained at that reorganized company under its new name, PE Corporation. It had been the Life Sciences division of Perkin-Elmer, and its two component tracking stock business groups, Celera Genomics (NYSE: CRA) and PE Biosystems (formerly NYSE: PEB), were centrally involved in the highest profile biotechnology events of the decade, the intense race against the Human Genome Project consortium, which then resulted in the genomics segment of the technology bubble. Perkin-Elmer purchased the Boston operations of NEN Life Sciences in 2001.
Recently
In 1992, the company merged with Applied Biosystems. In 1997 they merged with PerSeptive Biosystems. On July 14, 1999, the new analytical instruments maker PerkinElmer cut 350 jobs, or 12%, in its cost reduction reorganization. In 2006, PerkinElmer sold off the Fluid Sciences division for approximately US$400 million; the aim of the selloff was to increase the strategic focus on its higher-growth health sciences and photonic markets. Following on from the selloff, a number of small businesses were acquired, including Spectral Genomics, Improvision, Evotec-Technologies, Euroscreen, ViaCell, and Avalon Instruments. The brand "Evotec-Technologies" remains the property of Evotec, the former owner company. PerkinElmer had a license to use the brand until the end of year 2007.
PerkinElmer has continued to expand its interest in medicine with the acquisitions of clinical laboratories, In July 2006, it acquired NTD Labs located on Long Island, New York. The laboratory specializes in prenatal screening during the first trimester of pregnancy. In 2007, it purchased ViaCell, Inc. for US$300 million, which included its offices in Boston and cord blood storage facility in Kentucky near Cincinnati. The company was renamed ViaCord.
In 2001 Perkin Elmer acquired Packard Bioscience Inc from its majority shareholder, Dick McKernen. This acquisition also came with Agincourt Technologies Inc and consolidated Perkin Elmer's position in laboratory robotics, in particular, liquid handling robots which were to prove essential for the high-throughput sequencing needed for the Human Genome Project.
In March 2008, PerkinElmer purchased Pediatrix Screening (formerly Neo Gen Screening), a laboratory located in Bridgeville, Pennsylvania specializing in screening newborns for various inborn errors of metabolism such as phenylketonuria, hypothyroidism, and sickle-cell disease. It renamed the laboratory PerkinElmer Genetics, Inc.
In May 2011, PerkinElmer announced the signature of an agreement to acquire CambridgeSoft, and the successful acquisition of ArtusLabs.
In September 2011, PerkinElmer bought Caliper Life Sciences for US$600 million.
In December 2014 PerkinElmer acquired Perten Instruments for US$266 million to expand in food testing.
In January 2016, PerkinElmer acquired Swedish firm Vanadis Diagnostics.
In February 2016 PerkinElmer acquired Delta Instruments.
In January 2017, the company announced it would acquire the Indian in vitro diagnostic company, Tulip Diagnostics. In May 2017, the company acquired Euroimmun Medical Laboratory Diagnostics for approximately US$1.3 billion.
In 2018, the company acquired Australian biotech company, RHS Ltd., Chinese manufacturer of analytical instruments, Shanghai Spectrum Instruments Co. Ltd., and France-based company Cisbio Bioassays, which specializes in diagnostics and drug discovery solutions.
In November 2020, PerkinElmer announced it would acquire Horizon Discovery Group for around US$383 million.
In March 2021, PerkinElmer announced that the company has completed its acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). In May of the same year, the business announced it would purchase Nexcelom Bioscience for $260 million and Immunodiagnostic Systems Holdings PLC for $155 million. In June the company announced it would acquire SIRION Biotech, a specialist in viral vector gene delivery methods. In July the business announced it would acquire BioLegend for $5.25 billion.
Acquisition history
Programs
Hubble optics project
Perkin-Elmer's Danbury Optical System unit was commissioned to build the optical components of the Hubble Space Telescope. The construction of the main mirror began in 1979 and completed in 1981. The polishing process ran over budget and behind schedule, producing significant friction with NASA. Due to a miscalibrated null corrector, the primary mirror was also found to have a significant spherical aberration after reaching orbit on STS-31. Perkin-Elmer's own calculations and measurements revealed the primary mirror's surface discrepancies, but the company chose to withhold that data from NASA. A NASA investigation heavily criticized Perkin-Elmer for management failings, disregarding written quality guidelines, and ignoring test data that revealed the miscalibration. Corrective optics were installed on the telescope during the first Hubble service and repair mission STS-61. The correction, Corrective Optics Space Telescope Axial Replacement, was applied entirely to the secondary mirror and replaced existing instrumentation; the aberration of the primary mirror remained uncorrected.
The company agreed to pay US$15 million, essentially forgoing its fees in polishing the mirror, to avoid a threatened liability lawsuit under the False Claims Act by the Federal government. Hughes Aircraft, which acquired the Danbury Optical System unit one month after the launch of the telescope, paid US$10 million. The Justice Department asserted that the companies should have known about the flawed testing. Trade group Aerospace Industries Association protested when concerns were raised in the aerospace industry that aerospace companies might be held liable for failed equipment.
KH-9 Hexagon
Perkin-Elmer built the optical systems for the KH-9 Hexagon series of spy satellites at a facility in Danbury, Connecticut.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | RVTY | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | 46.75Y avg ≈34.7 | ≈34.7 | 46.0 | Overvalued | |
| P/S | 3.85Y avg ≈5.1 | ≈5.1 | 7.1 | Undervalued | |
| P/B (MRQ) | 2.35Y avg ≈2.2 | ≈2.2 | 6.8 | Undervalued | |
| EV / EBITDA | 17.35Y avg ≈19.0 | ≈19.0 | 25.4 | Undervalued | |
| Price / FCF | 21.35Y avg ≈291.5 | ≈291.5 | · | · | |
| Price / Cash Flow | 18.65Y avg ≈46.4 | ≈46.4 | 28.0 | Undervalued | |
| EV / Revenue | 4.65Y avg ≈6.1 | ≈6.1 | · | · | |
| EV / FCF | 25.85Y avg ≈341.5 | ≈341.5 | · | · | |
| Price / Tangible Book (MRQ) | 3.4 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | RVTY | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin | 12.5%5Y avg ≈16.9% | ≈16.9% | 17.4% | Weak | |
| EBITDA Margin | 26.7%5Y avg ≈30.0% | ≈30.0% | 18.6% | Weak | |
| Pretax Margin | 9.4%5Y avg ≈14.5% | ≈14.5% | 17.9% | Weak | |
| Net Profit Margin | 8.5%5Y avg ≈15.9% | ≈15.9% | 14.7% | Weak | |
| ROA | 2.0%5Y avg ≈4.2% | ≈4.2% | 9.8% | Weak | |
| ROE | 3.3%5Y avg ≈7.4% | ≈7.4% | 11.0% | Weak | |
| ROIC | 3.0%5Y avg ≈4.3% | ≈4.3% | 13.4% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | RVTY | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.45Y avg ≈0.5 | ≈0.5 | 0.2 | High debt | |
| Current Ratio (MRQ) | 1.85Y avg ≈2.3 | ≈2.3 | 1.8 | In line | |
| Quick Ratio | 1.35Y avg ≈1.5 | ≈1.5 | 1.0 | Strong liquidity | |
| Long-Term Debt / Equity (MRQ) | 0.45Y avg ≈0.5 | ≈0.5 | 0.4 | In line |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | RVTY | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 3.7%5Y avg ≈-5.1% | ≈-5.1% | · | · | |
| Revenue CAGR 3Y | -4.8%5Y avg ≈-8.4% | ≈-8.4% | · | · | |
| Revenue CAGR 5Y | -5.5% | · | · | · | |
| EPS YoY | -5.9%5Y avg ≈-12.6% | ≈-12.6% | · | · | |
| Net Income YoY | -10.8%5Y avg ≈-12.0% | ≈-12.0% | · | · | |
| EPS CAGR 3Y | -22.8%5Y avg ≈-21.0% | ≈-21.0% | · | · | |
| EPS CAGR 5Y | -20.4% | · | · | · | |
| Net Income CAGR 3Y | -24.9%5Y avg ≈-20.2% | ≈-20.2% | · | · | |
| Net Income CAGR 5Y | -19.8% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | RVTY | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.25Y avg ≈0.3 | ≈0.3 | 0.6 | Weak | |
| Receivables Turnover | 4.15Y avg ≈4.5 | ≈4.5 | 5.5 | Weak | |
| Revenue / Employee | ≈$259.6K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Jul 17, 2026 | $0.07 | USD | ≈0.25% |
| Apr 17, 2026 | $0.07 | USD | ≈0.30% |
| Jan 16, 2026 | $0.07 | USD | ≈0.25% |
| Oct 17, 2025 | $0.07 | USD | ≈0.30% |
| Jul 18, 2025 | $0.07 | USD | ≈0.30% |
| Apr 17, 2025 | $0.07 | USD | ≈0.30% |
| Jan 17, 2025 | $0.07 | USD | ≈0.24% |
| Oct 18, 2024 | $0.07 | USD | ≈0.23% |
| Jul 19, 2024 | $0.07 | USD | ≈0.26% |
| Apr 18, 2024 | $0.07 | USD | ≈0.28% |
| Jan 18, 2024 | $0.07 | USD | ≈0.26% |
| Oct 19, 2023 | $0.07 | USD | ≈0.28% |
| Jul 20, 2023 | $0.07 | USD | ≈0.22% |
| Apr 20, 2023 | $0.07 | USD | ≈0.21% |
| Jan 19, 2023 | $0.07 | USD | ≈0.21% |
| Oct 20, 2022 | $0.07 | USD | ≈0.22% |
| Jul 21, 2022 | $0.07 | USD | ≈0.19% |
| Apr 21, 2022 | $0.07 | USD | ≈0.18% |
| Jan 20, 2022 | $0.07 | USD | ≈0.16% |
| Oct 21, 2021 | $0.07 | USD | ≈0.16% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Jul 27, 2026 | $1.41 | $1.25 | 13.1% |
| March 31, 2026 | $1.06 | $1.04 | 2.3% | |
| Dec. 31, 2025 | $1.70 | $1.58 | 7.4% | |
| Sept. 30, 2025 | $1.18 | $1.16 | 1.7% | |
| June 30, 2025 | $1.18 | $1.16 | 1.5% | |
| March 31, 2025 | $1.01 | $0.97 | 4.3% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.76B | $2.75B | $3.31B | $3.83B | $3.78B | $2.88B | $2.78B | $2.26B | $2.12B | $2.10B | $2.24B | |
| Cost of Revenue | · | · | · | · | · | · | · | $1.44B | $709M | $665M | $696M | $708M | |
| Gross Profit | · | · | · | $1.99B | $2.43B | $2.11B | $1.40B | $1.34B | $1.07B | $1.01B | $964M | $1.00B | |
| R&D Expense | $216M | $197M | $217M | $222M | $200M | $146M | $189M | $194M | $139M | $124M | $113M | $108M | |
| SG&A Expense | $992M | $994M | $1.02B | $1.03B | $975M | $716M | $815M | $812M | $626M | $590M | $587M | $648M | |
| Operating Income | $357M | $347M | $301M | $743M | $1.26B | $867M | $362M | $324M | $296M | $295M | $251M | $165M | |
| Interest Expense | · | · | · | · | · | $50M | $64M | $67M | $44M | $42M | $38M | $36M | |
| Interest Income | $31M | $73M | $72M | $4M | $2M | $1M | $1M | $1M | $3M | $702.0K | $673.0K | $667.0K | |
| Other Non-op | $-88M | $-31M | $-118M | $-91M | $-3M | $-5M | $-6M | $-13M | $43M | $-15M | $-5M | $-6M | |
| Pretax Income | $268M | $316M | $183M | $652M | $1.20B | $800M | $237M | $258M | $297M | $244M | $209M | $124M | |
| Income Tax | $28M | $33M | $3M | $139M | $314M | $170M | $9M | $20M | $140M | $28M | $20M | $-6M | |
| Net Income | $241M | $270M | $693M | $569M | $943M | $728M | $228M | $238M | $293M | $234M | $212M | $158M | |
| EPS (Basic) | $2.07 | $2.21 | $5.56 | $4.51 | $8.12 | $6.52 | $2.06 | $2.15 | $2.67 | $2.14 | $1.89 | $1.40 | |
| EPS (Diluted) | $2.07 | $2.20 | $5.55 | $4.50 | $8.08 | $6.49 | $2.04 | $2.13 | $2.64 | $2.12 | $1.87 | $1.39 | |
| Shares (Basic) | 116,542,000 | 122,756,000 | 124,704,000 | 126,155,000 | 116,165,000 | 111,514,000 | 110,827,000 | 110,561,000 | 109,857,000 | 109,478,000 | 112,507,000 | 112,593,000 | |
| Shares (Diluted) | 116,595,000 | 122,822,000 | 124,812,000 | 126,426,000 | 116,674,000 | 112,085,000 | 111,501,000 | 111,534,000 | 110,859,000 | 110,313,000 | 113,315,000 | 113,739,000 | |
| EBITDA | $762M | $775M | $732M | $1.17B | $1.69B | $1.23B | $576M | $504M | $410M | $383M | $398M | $327M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $920M | $1.16B | $913M | $454M | $603M | $387M | $192M | $163M | $202M | $359M | $238M | $175M | |
| Short-term Investments | · | $0 | $690M | $0 | · | · | · | · | · | · | · | · | |
| Receivables | $745M | $632M | $633M | $613M | $708M | $1.16B | $725M | $633M | $552M | $426M | $415M | $471M | |
| Inventory | $379M | $368M | $428M | $405M | $426M | $515M | $357M | $338M | $352M | $247M | $259M | $285M | |
| Other Current Assets | $196M | $186M | $337M | $122M | $148M | $167M | $100M | $101M | $94M | $99M | $64M | $138M | |
| Current Assets | $2.24B | $2.35B | $3.00B | $3.29B | $2.44B | $2.24B | $1.37B | $1.23B | $1.20B | $1.19B | $1.03B | $1.07B | |
| PP&E (Net) | $479M | $482M | $510M | $483M | $486M | $368M | $318M | $319M | $298M | $145M | $138M | $176M | |
| PP&E (Gross) | $1.09B | $982M | $983M | $857M | $844M | $818M | $702M | $680M | $631M | $428M | $402M | $493M | |
| Accum. Depreciation | $614M | $500M | $473M | $374M | $359M | $450M | $383M | $362M | $333M | $282M | $264M | $317M | |
| Goodwill | $6.61B | $6.46B | $6.53B | $6.48B | $6.63B | $2.64B | $3.11B | $2.95B | $3.00B | $2.25B | $2.24B | $2.24B | |
| Intangibles | $2.35B | $2.64B | $3.02B | $3.38B | $3.82B | $1.37B | $1.28B | $1.20B | $1.35B | $420M | $486M | $490M | |
| Other Non-current Assets | $323M | $288M | $343M | $311M | $317M | $333M | $284M | $270M | $244M | $205M | $198M | $107M | |
| Total Assets | $12.17B | $12.39B | $13.56B | $14.13B | $15.00B | $7.96B | $6.54B | $5.98B | $6.09B | $4.28B | $4.17B | $4.13B | |
| Accounts Payable | $185M | $167M | $204M | $273M | $325M | $327M | $236M | $221M | $222M | $168M | $141M | $174M | |
| Accrued Liabilities | $557M | $485M | $524M | $528M | $679M | $944M | $503M | $529M | $501M | $400M | $382M | $403M | |
| Current Liabilities | $1.33B | $653M | $1.45B | $1.54B | $1.21B | $1.65B | $763M | $772M | $951M | $603M | $561M | $597M | |
| Capital Leases | $148M | $152M | $133M | $170M | $147M | $188M | $146M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | $30M | |
| Other Non-current Liabilities | $807M | $771M | $931M | $1.11B | $1.43B | $775M | $751M | $742M | $849M | $460M | $465M | $443M | |
| Total Liabilities | $4.92B | $4.73B | $5.69B | $6.75B | $7.86B | $4.22B | $3.72B | $3.39B | $3.59B | $2.12B | $2.06B | $2.09B | |
| Long-term Debt | $3.22B | $3.15B | $3.90B | $4.39B | $4.98B | $1.99B | $2.07B | $1.89B | $2.01B | $1.05B | $480M | $1.05B | |
| Total Debt | $3.22B | $3.15B | $3.90B | $4.39B | $4.98B | $1.61B | $2.06B | $1.88B | $1.79B | $1.05B | $1.01B | $1.05B | |
| Common Stock | $112M | $121M | $123M | $126M | $126M | $112M | $111M | $111M | $110M | $110M | $112M | $112M | |
| Retained Earnings | $6.05B | $5.85B | $5.61B | $4.95B | $4.42B | $3.51B | $2.81B | $2.60B | $2.38B | $2.12B | $1.99B | $1.81B | |
| AOCI | $-222M | $-396M | $-277M | $-447M | $-163M | $-32M | $-200M | $-176M | $-47M | $-101M | $-46M | $25M | |
| Stockholders' Equity | $7.25B | $7.67B | $7.87B | $7.38B | $7.14B | $3.74B | $2.81B | $2.58B | $2.50B | $2.15B | $2.11B | $2.04B | |
| Liabilities + Equity | $12.17B | $12.39B | $13.56B | $14.13B | $15.00B | $7.96B | $6.54B | $5.98B | $6.09B | $4.28B | $4.17B | $4.13B | |
| Shares Outstanding | 112,281,000 | 120,646,000 | 0 | 126,300,000 | 126,241,000 | 112,090,000 | 111,140,000 | 110,361,000 | 110,361,000 | 109,617,000 | 112,481,000 | 112,481,000 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $405M | $428M | $432M | $427M | $311M | $202M | $214M | $181M | $105M | $100M | $105M | $110M | |
| Stock-based Comp | $23M | $38M | $41M | $52M | $30M | $27M | $32M | $29M | $25M | $17M | $17M | $14M | |
| Deferred Tax | $-61M | $-102M | $-124M | $-106M | $-55M | $-35M | $-61M | $-51M | $29M | $-5M | $-10M | $-34M | |
| Amort. of Intangibles | $336M | $359M | $365M | $371M | $257M | $161M | $164M | $136M | $74M | $72M | $77M | $81M | |
| Restructuring | · | $18M | $27M | $14M | $-14M | $8M | $29M | $11M | $13M | $5M | $14M | $13M | |
| Other Non-cash | $-25M | $-6M | $-951M | $-262M | $126M | $-82M | $-48M | $-85M | $-163M | $4M | $-48M | $26M | |
| Operating Cash Flow | $583M | $628M | $91M | $680M | $1.41B | $892M | $363M | $311M | $288M | $351M | $287M | $282M | |
| CapEx | $74M | $87M | $81M | $86M | $86M | $64M | $76M | $93M | $39M | $32M | $28M | $27M | |
| Investing Cash Flow | $-17M | $776M | $1.31B | $-133M | $-4.11B | $-504M | $-488M | $-160M | $-1.27B | $-84M | $-101M | $-296M | |
| Stock Repurchased | $821M | $370M | $389M | $81M | $73M | $7M | $6M | $57M | $4M | $152M | $76M | $66M | |
| Net Stock Activity | $-821M | $-370M | $-389M | $-81M | $-73M | $-7M | $-6M | $-57M | $-4M | $-152M | $-76M | $-66M | |
| Dividends Paid | $33M | $34M | $35M | $35M | $32M | $31M | $31M | $31M | $31M | $31M | $32M | $32M | |
| Financing Cash Flow | $-858M | $-1.13B | $-947M | $-662M | $2.94B | $-203M | $-150M | $-179M | $782M | $-115M | $-107M | $31M | |
| Net Change in Cash | $-243M | $250M | $444M | $-149M | $217M | $211M | $26M | $-36M | $-174M | $138M | $63M | $2M | |
| Taxes Paid | $131M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $509M | $542M | $10M | $594M | $1.31B | $815M | $287M | $218M | $249M | $319M | $257M | $253M | |
| Levered FCF | · | · | · | · | · | $775M | $226M | $156M | $226M | $282M | $224M | $218M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | 60.1% | · | 55.8% | 48.4% | 48.3% | 47.5% | 47.9% | 45.3% | 44.9% | |
| Operating Margin | 12.5% | 12.6% | 10.9% | 22.4% | 26.3% | 25.9% | 12.6% | 11.7% | 13.5% | 13.4% | 12.7% | 9.4% | |
| Net Margin | 8.5% | 9.8% | 25.2% | 17.2% | 18.6% | 19.2% | 7.9% | 8.6% | 13.0% | 11.1% | 9.4% | 7.0% | |
| Pretax Margin | 9.4% | 11.5% | 6.7% | 19.7% | 25.3% | 24.0% | 8.2% | 9.3% | 13.2% | 11.5% | 10.8% | 7.6% | |
| EBITDA Margin | 26.7% | 28.1% | 26.6% | 35.3% | 33.4% | 32.4% | 20.0% | 18.2% | 18.2% | 18.1% | 17.6% | 14.6% | |
| ROA | 2.0% | 2.1% | 5.0% | 3.9% | 8.2% | 10.0% | 3.6% | 3.9% | 5.6% | 5.5% | 5.1% | 3.9% | |
| ROE | 3.3% | 3.5% | 8.9% | 7.9% | 13.4% | 20.9% | 8.2% | 9.2% | 12.6% | 11.0% | 10.2% | 7.8% | |
| ROIC | 3.0% | 2.9% | 2.5% | 5.0% | 8.1% | 14.7% | 7.1% | 6.7% | 3.8% | 7.8% | 8.0% | 6.5% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | 3.6 | 2.1 | 2.1 | 2.0 | 1.4 | 1.8 | 1.6 | 1.3 | 2.0 | 1.8 | 1.8 | |
| Quick Ratio | 1.3 | 2.7 | 1.5 | 0.7 | 1.4 | 0.9 | 1.2 | 1.0 | 0.8 | 1.3 | 1.2 | 1.1 | |
| Debt / Equity | 0.4 | 0.4 | 0.5 | 0.6 | 0.7 | 0.4 | 0.7 | 0.7 | 0.7 | 0.5 | 0.5 | 0.5 | |
| LT Debt / Equity | 0.4 | 0.4 | 0.4 | 0.5 | 0.7 | 0.4 | 0.7 | 0.7 | 0.7 | 0.5 | 0.5 | 0.5 | |
| Interest Coverage | · | · | · | · | · | 19.7 | 5.7 | 4.8 | 6.9 | 6.8 | 7.5 | 5.8 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | 0.2 | 0.2 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4 | 0.5 | 0.5 | 0.6 | |
| Inventory Turnover | · | · | · | · | · | · | · | 4.2 | 2.4 | 2.6 | 2.8 | 2.9 | |
| Receivables Turnover | 4.1 | 4.4 | 4.4 | 5.0 | 4.7 | 4.0 | 4.2 | 4.7 | 4.6 | 5.0 | 5.0 | 4.8 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $64.57 | $63.55 | $63.79 | $58.46 | $56.57 | $33.33 | $25.44 | $23.37 | $22.68 | $19.22 | $18.84 | $18.16 | |
| Revenue / Share | $24.50 | $22.43 | $22.04 | $26.20 | $43.43 | $33.75 | $25.86 | $24.91 | $20.36 | $19.18 | $19.97 | $19.67 | |
| Cash Flow / Share | $5.00 | $5.12 | $0.73 | $5.38 | $12.09 | $7.96 | $3.26 | $2.79 | $2.60 | $3.18 | $2.53 | $2.48 | |
| Cash / Share | $8.19 | $9.64 | $7.40 | $3.60 | $4.90 | $3.59 | $1.73 | $1.47 | $1.83 | $3.21 | $2.12 | $1.55 | |
| Dividend / Share | $0.28 | $0.28 | $0.28 | $0.28 | · | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | |
| EPS (TTM) | $2.07 | $2.20 | $5.55 | $4.50 | $8.08 | $6.49 | $2.04 | $2.13 | $2.64 | $2.12 | $1.87 | $1.39 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 3.7% | 0.16% | -17.0% | -13.5% | 1.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -4.8% | -10.4% | -10.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -5.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -5.9% | -60.4% | 23.3% | -44.3% | 24.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -22.8% | -35.2% | -5.1% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -20.4% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -10.8% | -61.0% | 21.8% | -39.6% | 29.6% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -24.9% | -34.1% | -1.6% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -19.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 1.0% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.86B | $2.76B | $2.75B | $3.31B | $3.83B | $3.78B | $2.88B | $2.78B | $2.26B | $2.12B | $2.10B | $2.24B | |
| Net Income TTM | $241M | $270M | $693M | $569M | $943M | $728M | $228M | $238M | $293M | $234M | $212M | $158M | |
| Market Cap | $10.86B | $13.51B | $13.49B | $17.71B | $25.38B | $16.08B | $10.73B | $8.55B | $8.07B | $5.84B | $6.00B | $4.96B | |
| Enterprise Value | $13.16B | $15.50B | $15.79B | $21.65B | $29.74B | $17.29B | $12.61B | $10.26B | $9.66B | $6.53B | $6.78B | $5.83B | |
| P/E | 46.7 | 50.9 | 19.7 | 31.2 | 24.9 | 22.1 | 47.6 | 36.3 | 27.7 | 24.6 | 28.6 | 31.7 | |
| P/S | 3.8 | 4.9 | 4.9 | 5.3 | 6.6 | 4.3 | 3.7 | 3.1 | 3.6 | 2.8 | 2.9 | 2.2 | |
| P/B | 1.5 | 1.8 | 1.7 | 2.4 | 3.6 | 4.3 | 3.8 | 3.3 | 3.2 | 2.7 | 2.8 | 2.4 | |
| P / Cash Flow | 18.6 | 21.5 | 147.8 | 26.1 | 18.0 | 18.0 | 29.5 | 27.5 | 28.0 | 16.7 | 20.9 | 17.6 | |
| P / FCF | 21.3 | 24.9 | 1362.2 | 29.8 | 19.4 | 19.7 | 37.4 | 39.2 | 32.4 | 18.3 | 23.3 | 19.6 | |
| EV / EBITDA | 17.3 | 20.0 | 21.6 | 18.5 | 17.6 | 14.1 | 21.9 | 20.3 | 23.6 | 17.0 | 17.0 | 17.8 | |
| EV / FCF | 25.8 | 28.6 | 1594.1 | 36.4 | 22.7 | 21.2 | 43.9 | 47.1 | 38.7 | 20.5 | 26.3 | 23.1 | |
| EV / Revenue | 4.6 | 5.6 | 5.7 | 6.5 | 7.8 | 4.6 | 4.4 | 3.7 | 4.3 | 3.1 | 3.2 | 2.6 | |
| Dividend Yield | 0.30% | 0.26% | 0.26% | 0.20% | 0.13% | 0.19% | 0.29% | 0.36% | 0.38% | 0.53% | 0.53% | 0.64% | |
| Earnings Yield | 2.1% | 2.0% | 5.1% | 3.2% | 4.0% | 4.5% | 2.1% | 2.8% | 3.6% | 4.1% | 3.5% | 3.1% | |
| Payout Ratio | 13.6% | 12.7% | 5.0% | 6.2% | 3.4% | 4.3% | 13.7% | 13.0% | 10.5% | 13.2% | 14.9% | 20.0% | |
| Annual Payout | $33M | $34M | $35M | $35M | $32M | $31M | $31M | $31M | $31M | $31M | $32M | $32M |
Income Statement
| Metric | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $730M | $711M | $772M | $699M | $720M | $665M | $729M | $684M | $692M | $650M | $403M | $709M | $-120M | |
| Cost of Revenue | $313M | $323M | · | $324M | $328M | $289M | · | $299M | $306M | $295M | · | $307M | · | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | · | · | $436M | |
| R&D Expense | $49M | $58M | $58M | $51M | $53M | $54M | $49M | $49M | $48M | $50M | $45M | $57M | $40M | |
| SG&A Expense | $279M | $254M | $252M | $242M | $249M | $250M | $244M | $238M | $252M | $261M | $232M | $267M | $229M | |
| Operating Income | $89M | $76M | $112M | $82M | $91M | $72M | $119M | $98M | $86M | $44M | $-116M | $78M | $-290M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $24M | · | $26M | · | |
| Interest Income | $5M | $6M | $6M | $7M | $8M | $10M | $10M | $23M | $21M | $20M | $41M | $25M | $2M | |
| Other Non-op | $21M | $-26M | $-77M | $-4M | $13M | $-20M | $-26M | $-1M | $43M | $-10M | $-27M | $-7M | $-66M | |
| Pretax Income | $64M | $50M | $92M | $56M | $69M | $52M | $95M | $100M | $87M | $35M | $-143M | $72M | $-361M | |
| Income Tax | $10M | $9M | $-4M | $8M | $13M | $11M | $6M | $7M | $14M | $6M | $-55M | $13M | $-87M | |
| Net Income | $52M | $41M | $98M | $47M | $54M | $42M | $95M | $94M | $55M | $26M | $-89M | $36M | $-166M | |
| EPS (Basic) | $0.47 | $0.36 | $0.86 | $0.40 | $0.46 | $0.35 | $0.78 | $0.77 | $0.45 | $0.21 | $-0.63 | $0.28 | $-2.50 | |
| EPS (Diluted) | $0.47 | $0.36 | $0.86 | $0.40 | $0.46 | $0.35 | $0.77 | $0.77 | $0.45 | $0.21 | $-0.63 | $0.28 | $-2.48 | |
| Shares (Basic) | 111,584,000 | 111,852,000 | · | 115,411,000 | 117,512,000 | 120,137,000 | · | 122,810,000 | 123,354,000 | 123,428,000 | · | 125,215,000 | · | |
| Shares (Diluted) | 111,629,000 | 111,876,000 | · | 115,463,000 | 117,538,000 | 120,233,000 | · | 123,026,000 | 123,477,000 | 123,538,000 | · | 125,398,000 | · | |
| EBITDA | $89M | $181M | · | $82M | $91M | $170M | · | $98M | $86M | $152M | · | $78M | · |
Balance Sheet
| Metric | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.02B | $860M | $920M | $931M | $992M | $1.14B | $1.16B | $1.23B | $1.25B | $998M | $913M | $1.33B | $454M | |
| Short-term Investments | · | · | · | · | · | · | · | $0 | $706M | $697M | · | $739M | · | |
| Receivables | $709M | $691M | $745M | $680M | $661M | $617M | $632M | $602M | $597M | $589M | · | $627M | · | |
| Inventory | $379M | $388M | $379M | $380M | $388M | $381M | $368M | $405M | $401M | $414M | · | $437M | · | |
| Other Current Assets | $187M | $189M | $196M | $152M | $195M | $182M | $186M | $212M | $206M | $361M | · | $389M | · | |
| Current Assets | $2.30B | $2.13B | $2.24B | $2.14B | $2.24B | $2.32B | $2.35B | $2.45B | $3.16B | $3.06B | · | $3.52B | · | |
| PP&E (Net) | $456M | $466M | $479M | $497M | $499M | $487M | $482M | $518M | $503M | $504M | · | $491M | · | |
| PP&E (Gross) | · | · | $1.09B | · | · | · | $982M | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $614M | · | · | · | $500M | · | · | · | · | · | · | |
| Goodwill | $6.61B | $6.61B | $6.61B | $6.60B | $6.61B | $6.51B | $6.46B | $6.56B | $6.50B | $6.50B | $6.53B | $6.52B | $6.48B | |
| Intangibles | $2.22B | $2.31B | $2.35B | $2.43B | $2.51B | $2.57B | $2.64B | $2.76B | $2.83B | $2.92B | · | $3.20B | · | |
| Other Non-current Assets | $309M | $322M | $323M | $300M | $321M | $300M | $288M | $332M | $297M | $298M | · | $322M | · | |
| Total Assets | $12.05B | $12.00B | $12.17B | $12.14B | $12.36B | $12.36B | $12.39B | $12.77B | $13.42B | $13.43B | · | $14.22B | · | |
| Accounts Payable | $166M | $170M | $185M | $176M | $178M | $178M | $167M | $176M | $175M | $184M | · | $236M | · | |
| Accrued Liabilities | $538M | $493M | $557M | $463M | $493M | $470M | $485M | $510M | $504M | $479M | · | $652M | · | |
| Current Liabilities | $1.28B | $1.24B | $1.33B | $1.22B | $672M | $648M | $653M | $688M | $1.39B | $1.37B | · | $1.37B | · | |
| Capital Leases | $136M | $142M | $148M | $154M | $160M | $157M | $152M | $128M | $123M | $127M | · | $144M | · | |
| Other Non-current Liabilities | $771M | $801M | $807M | $755M | $760M | $750M | $771M | $846M | $879M | $920M | · | $954M | · | |
| Total Liabilities | $4.82B | $4.81B | $4.92B | $4.76B | $4.81B | $4.72B | $4.73B | $4.85B | $5.55B | $5.59B | · | $6.35B | · | |
| Long-term Debt | $3.21B | $3.21B | $3.22B | $3.21B | $3.21B | $3.17B | $3.15B | $3.19B | $3.87B | $3.88B | · | $4.36B | · | |
| Total Debt | $3.21B | $3.21B | · | $3.21B | $3.21B | $3.17B | · | $3.19B | $3.87B | $3.88B | · | · | · | |
| Common Stock | $112M | $112M | $112M | $114M | $116M | $119M | $121M | $122M | $123M | $123M | · | $124M | · | |
| Retained Earnings | $6.13B | $6.09B | $6.05B | $5.96B | $5.93B | $5.88B | $5.85B | $5.76B | $5.67B | $5.63B | · | $5.54B | · | |
| AOCI | $-257M | $-254M | $-222M | $-180M | $-157M | $-316M | $-396M | $-232M | $-342M | $-325M | $-277M | $-305M | $-447M | |
| Stockholders' Equity | $7.23B | $7.18B | $7.25B | $7.38B | $7.56B | $7.64B | $7.67B | $7.92B | $7.87B | $7.85B | $7.87B | $7.87B | $7.38B | |
| Liabilities + Equity | $12.05B | $12.00B | $12.17B | $12.14B | $12.36B | $12.36B | $12.39B | $12.77B | $13.42B | $13.43B | · | $14.22B | · | |
| Shares Outstanding | 111,584,000 | 111,629,000 | 112,281,000 | 114,030,000 | 116,331,000 | 119,409,000 | 120,646,000 | 122,091,000 | 123,368,000 | 123,492,000 | 0 | 124,347,000 | 0 |
Cash Flow
| Metric | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $102M | $105M | $103M | $102M | $103M | $97M | $105M | $108M | $106M | $108M | $106M | · | $104M | |
| Stock-based Comp | $11M | $9M | $-4M | $9M | $10M | $8M | $5M | $11M | $12M | $12M | $7M | · | $12M | |
| Amort. of Intangibles | $85M | $85M | $84M | $84M | $85M | $83M | $88M | $90M | $91M | $91M | $85M | $93M | $163M | |
| Other Non-cash | · | $-39M | · | · | · | $-19M | · | · | · | $2M | · | · | · | |
| Operating Cash Flow | $192M | $115M | $182M | $138M | $134M | $128M | $174M | $148M | $243M | $148M | $197M | · | $139M | |
| CapEx | $11M | $20M | $20M | $19M | $19M | $16M | $24M | $22M | $19M | $18M | $24M | · | $26M | |
| Investing Cash Flow | $-4M | $-78M | $-20M | $19M | $-9M | $-6M | $-17M | $690M | $-1.76B | $-18M | $-415M | · | $-26M | |
| Stock Repurchased | $16M | $86M | $168M | $205M | $294M | $154M | $185M | $154M | $-31M | $11M | $5M | · | $25M | |
| Net Stock Activity | · | $-86M | · | · | · | $-154M | · | · | · | $-11M | · | · | · | |
| Dividends Paid | $8M | $8M | $8M | $8M | $8M | $8M | $9M | $9M | $8M | $9M | $9M | · | $9M | |
| Financing Cash Flow | $-23M | $-89M | $-176M | $-215M | $-302M | $-164M | $-193M | $-874M | $52M | $-35M | $-20M | · | $-77M | |
| Net Change in Cash | $163M | $-60M | $-12M | $-60M | $-146M | $-26M | $-66M | $-19M | $-1.46B | $85M | $-224M | · | $54M | |
| Free Cash Flow | · | $95M | · | · | · | $112M | · | · | · | $130M | · | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $109M | · | · | · |
Profitability
| Metric | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.2% | 10.7% | · | 11.7% | 12.6% | 10.9% | · | 14.3% | 12.4% | 6.8% | · | 11.0% | · | |
| Net Margin | 7.1% | 5.7% | · | 6.7% | 7.5% | 6.3% | · | 13.8% | 8.0% | 4.0% | · | 5.0% | · | |
| Pretax Margin | 8.7% | 7.0% | · | 8.0% | 9.5% | 7.9% | · | 14.7% | 12.5% | 5.3% | · | 10.1% | · | |
| EBITDA Margin | 12.2% | 25.4% | · | 11.7% | 12.6% | 25.5% | · | 14.3% | 12.4% | 23.4% | · | 11.0% | · | |
| ROA | 0.42% | 0.33% | · | 0.37% | 0.42% | 0.33% | · | 0.72% | 0.40% | 0.19% | · | · | · | |
| ROE | 0.70% | 0.55% | · | 0.61% | 0.70% | 0.55% | · | 1.2% | 0.70% | 0.33% | · | · | · | |
| ROIC | 0.72% | 0.60% | · | 0.66% | 0.68% | 0.53% | · | 0.82% | 0.61% | 0.31% | · | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | 1.7 | · | 1.8 | 3.3 | 3.6 | · | 3.6 | 2.3 | 2.2 | · | · | · | |
| Quick Ratio | 1.4 | 1.3 | · | 1.3 | 2.5 | 2.7 | · | 2.7 | 1.8 | 1.7 | · | · | · | |
| Debt / Equity | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.5 | 0.5 | · | · | · | |
| LT Debt / Equity | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 3.5 | 1.8 | · | 3.0 | · |
Efficiency
| Metric | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | · | · | |
| Inventory Turnover | 0.8 | 0.8 | · | 0.8 | 0.8 | 0.7 | · | 0.7 | 0.7 | 0.7 | · | · | · | |
| Receivables Turnover | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | · | · |
Per Share
| Metric | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $64.78 | $64.34 | · | $64.68 | $64.95 | $63.96 | · | $64.88 | $63.80 | $63.54 | · | · | · | |
| Revenue / Share | $6.54 | $6.36 | · | $6.05 | $6.13 | $5.53 | · | $5.56 | $5.60 | $5.26 | · | $5.65 | · | |
| Cash Flow / Share | · | $1.03 | · | · | · | $1.07 | · | · | · | $1.19 | · | · | · | |
| Cash / Share | $9.17 | $7.71 | · | $8.17 | $8.53 | $9.53 | · | $10.07 | $10.12 | $8.08 | · | · | · | |
| Dividend / Share | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | |
| Dividend Paid / Share | · | · | · | · | · | · | · | $0.07 | $0.07 | $0.07 | · | $0.07 | · | |
| EPS (TTM) | $2.09 | $2.08 | · | $1.98 | $2.35 | $2.34 | · | $0.80 | $0.11 | $-0.06 | · | · | $4.50 |
Valuation (TTM)
| Metric | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.91B | $2.90B | · | $2.81B | $2.80B | $2.77B | · | $2.43B | $2.42B | $2.43B | · | · | $3.31B | |
| Net Income TTM | · | · | · | $237M | $285M | $287M | · | $87M | $2M | $-18M | · | · | $569M | |
| Market Cap | $12.69B | $9.93B | · | $9.59B | $11.38B | $12.61B | · | $15.39B | $12.94B | $12.97B | · | · | · | |
| Enterprise Value | $14.88B | $12.28B | · | $11.87B | $13.60B | $14.64B | · | $17.35B | $14.86B | $15.15B | · | · | · | |
| P/E | 54.4 | 42.8 | · | 42.5 | 41.6 | 45.1 | · | 157.6 | 953.3 | -1750.0 | · | · | 31.2 | |
| P/S | 4.4 | · | · | 3.4 | 4.1 | 4.6 | · | 6.3 | 5.4 | 5.3 | · | · | · | |
| P/B | 1.8 | 1.4 | · | 1.3 | 1.5 | 1.7 | · | 1.9 | 1.6 | 1.7 | · | · | · | |
| P / Cash Flow | · | 86.2 | · | · | · | 98.4 | · | · | · | 87.9 | · | · | · | |
| EV / Revenue | 5.1 | · | · | 4.2 | 4.9 | 5.3 | · | 7.1 | 6.1 | 6.2 | · | · | · | |
| Dividend Yield | 0.25% | · | · | 0.35% | 0.30% | 0.27% | · | 0.22% | 0.27% | · | · | · | · | |
| Earnings Yield | 1.8% | 2.3% | · | 2.4% | 2.4% | 2.2% | · | 0.63% | 0.10% | -0.06% | · | · | 3.2% | |
| Payout Ratio | · | 19.2% | · | · | · | 20.0% | · | · | · | 33.2% | · | · | · | |
| Annual Payout | $32M | $32M | · | $33M | $34M | $34M | · | $34M | $34M | · | · | · | $35M |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 |
|---|---|---|---|---|---|
| Revenue | $2.86B | $2.76B | $2.75B | $3.31B | $3.83B |
| Gross Margin % | · | · | · | 60.1% | · |
| Operating Margin % | 12.5% | 12.6% | 10.9% | 22.4% | 26.3% |
| Net Income | $241M | $270M | $693M | $569M | $943M |
| Diluted EPS | $2.07 | $2.20 | $5.55 | $4.50 | $8.08 |
| Metric | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 |
|---|---|---|---|---|---|
| Debt / Equity | 0.4 | 0.4 | 0.5 | 0.6 | 0.7 |
| Current Ratio | 1.7 | 3.6 | 2.1 | 2.1 | 2.0 |
| Quick Ratio | 1.3 | 2.7 | 1.5 | 0.7 | 1.4 |
| Metric | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 |
|---|---|---|---|---|---|
| Free Cash Flow | $509M | $542M | $10M | $594M | $1.31B |
Institutional owners (13F) 579 filers · $11.1B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 101 (+19 vs prior Q) | 53 (-14 vs prior Q) | 195 (+16 vs prior Q) | 163 (+4 vs prior Q) | -8.8M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1,273,316,785 | 13,160,897 | 11.42% | Shares |
| EdgePoint Investment Group Inc. | $950,658,734 | 8,544,479 | 8.53% | Shares |
| BlackRock, Inc. | $852,070,090 | 7,658,369 | 7.64% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $812,306,256 | 7,300,973 | 7.29% | Shares |
| JANUS HENDERSON GROUP PLC | $731,386,229 | 8,348,127 | 6.56% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $530,760,044 | 4,770,448 | 4.76% | Shares |
| STATE STREET CORP | $483,173,141 | 4,342,739 | 4.33% | Shares |
| VICTORY CAPITAL MANAGEMENT INC | $384,362,134 | 3,454,630 | 3.45% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $381,477,581 | 3,428,692 | 3.42% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $328,197,297 | 2,955,227 | 2.94% | Shares |
| MORGAN STANLEY | $286,475,399 | 2,574,826 | 2.57% | Shares |
| Invesco Ltd. | $269,802,164 | 2,424,970 | 2.42% | Shares |
| Allspring Global Investments Holdings, LLC | $251,393,303 | 2,227,874 | 2.25% | Shares |
| NEUBERGER BERMAN GROUP LLC | $208,728,363 | 1,876,041 | 1.87% | Shares |
| UBS Group AG | $207,440,264 | 1,864,464 | 1.86% | Shares |
| Pictet Asset Management Holding SA | $181,501,112 | 1,631,343 | 1.63% | Shares |
| CITADEL ADVISORS LLC | $162,143,092 | 1,457,335 | 1.45% | Shares |
| RGM Capital, LLC | $147,000,789 | 1,519,388 | 1.32% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $120,784,746 | 1,085,608 | 1.08% | Shares |
| VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P. | $120,187,725 | 1,080,242 | 1.08% | Shares |
| NORTHERN TRUST CORP | $105,092,080 | 944,563 | 0.94% | Shares |
| GOLDMAN SACHS GROUP INC | $100,173,074 | 900,351 | 0.90% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $96,303,874 | 865,575 | 0.86% | Shares |
| NORGES BANK | $96,183,046 | 864,489 | 0.86% | Shares |
| PRIMECAP MANAGEMENT CO/CA/ | $94,921,470 | 853,150 | 0.85% | Shares |
| BANK OF AMERICA CORP /DE/ | $87,116,298 | 782,997 | 0.78% | Shares |
| Bank of New York Mellon Corp | $78,765,533 | 707,941 | 0.71% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $69,620,945 | 625,750 | 0.62% | Shares |
| JANE STREET GROUP, LLC | $64,087,317 | 576,014 | 0.57% | Shares |
| JPMORGAN CHASE & CO | $54,177,057 | 481,955 | 0.49% | Shares |
| FMR LLC | $51,807,384 | 465,642 | 0.46% | Shares |
| SEI INVESTMENTS CO | $48,628,856 | 437,074 | 0.44% | Shares |
| Quantinno Capital Management LP | $47,076,898 | 423,125 | 0.42% | Shares |
| DEUTSCHE BANK AG\ | $45,437,583 | 408,391 | 0.41% | Shares |
| FEDERATED HERMES, INC. | $43,043,267 | 386,871 | 0.39% | Shares |
| Diamond Hill Capital Management, LLC (Investment Advisor) | $42,868,033 | 385,296 | 0.38% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $41,752,209 | 476,569 | 0.37% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $41,048,042 | 368,938 | 0.37% | Shares |
| Freestone Grove Partners LP | $36,716,134 | 330,003 | 0.33% | Shares |
| Legal & General Group Plc | $31,388,230 | 282,116 | 0.28% | Shares |
| CIBC Bancorp USA Inc. | $29,112,955 | 261,625 | 0.26% | Shares |
| Nuveen, LLC | $27,202,014 | 244,491 | 0.24% | Shares |
| California Public Employees Retirement System | $27,021,271 | 242,866 | 0.24% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $25,920,242 | 232,970 | 0.23% | Shares |
| WEDGE CAPITAL MANAGEMENT L L P/NC | $25,784,587 | 294,311 | 0.23% | Shares |
| Vanguard Global Advisers, LLC | $25,557,201 | 229,707 | 0.23% | Shares |
| Swiss National Bank | $24,955,618 | 224,300 | 0.22% | Shares |
| CIBC Private Wealth Group LLC | $23,946,556 | 273,207 | 0.21% | Shares |
| Artisan Partners Limited Partnership | $22,320,536 | 200,616 | 0.20% | Shares |
| Meridiem Capital Partners LP | $21,483,638 | 193,094 | 0.19% | Shares |
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| PERKINELMER, INC. | Sept. 16, 2011 | · | Initial filing | M&A / sale | SEC |
| Undisclosed reporting person | July 23, 2001 | · | Initial filing | M&A / sale | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 46 insiders · 27 officers · 20 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Robert F Friel | Chairman and CEO | Feb. 13, 2019 F | 570,662 | 0 | 0 | $0 |
| Maxwell Krakowiak | Senior Vice President and Chief Financial Officer | Sept. 21, 2026 S | 14,781 | 0 | 1 | $-235,728 |
| James M Mock | Senior Vice President and Chief Financial Officer | June 24, 2022 S | 27,577 | 0 | 0 | $0 |
| Frank Anders Wilson | Senior Vice President and Chief Financial Officer | March 5, 2018 M | 61,925 | 0 | 0 | $0 |
| Jeffrey D Capello | SVP & CFO | Jan. 29, 2008 A | 91,428 | 0 | 0 | $0 |
| John Patrick Murphy | Chief Operating Officer | Aug. 1, 2005 M | 68,589 | 0 | 0 | $0 |
| Anita Gonzales | VP and CAO | Oct. 1, 2026 S | 7,117 | 0 | 3 | $-29,790 |
| Tajinder Vohra | Senior Vice President, Global Operations | Sept. 16, 2026 S | 6,635 | 0 | 2 | $-1,634,152 |
| Joel S Goldberg | Senior Vice President, Administration, General Counsel and Secretary | Aug. 14, 2026 G | 91,494 | 0 | 4 | $-1,274,357 |
| Miriame Victor | Senior Vice President, Chief Commercial Officer | Feb. 24, 2026 M | 18,122 | 0 | 1 | $-180,856 |
| Daniel R Tereau | Senior Vice President, Strategy and Business Development | Feb. 5, 2024 A | 13,246 | 0 | 0 | $0 |
| Andrew Okun | Vice President, Chief Accounting Officer and Treasurer | April 13, 2023 M | 4,356 | 0 | 0 | $0 |
| Deborah A. Butters | Senior Vice President, Chief Human Resources Officer | Feb. 7, 2020 F | 12,383 | 0 | 0 | $0 |
| James Corbett | Executive Vice President and President, Discovery & Analytical Solutions | April 30, 2019 F | 40,531 | 0 | 0 | $0 |
| Jonathan P. Divincenzo | Senior Vice President and President, Environmental Health | Feb. 9, 2016 A | 23,158 | 0 | 0 | $0 |
| John R Letcher | Senior Vice President, Human Resources | June 5, 2015 D | 26,894 | 0 | 0 | $0 |
| Maurice H. Tenney | Senior Vice President, Global Operations and Customer Logistics | Nov. 7, 2014 D | 12,241 | 0 | 0 | $0 |
| Daniel R Marshak | SVP & CSO | Sept. 26, 2014 D | 67,743 | 0 | 0 | $0 |
| Kevin E Hrusovsky | Senior Vice President, President Life Sciences and Technology | May 31, 2013 D | 0 | 0 | 0 | $0 |
| John A Roush | Senior Vice President | Feb. 9, 2010 A | 120,407 | 0 | 0 | $0 |
| Richard F Walsh | SVP & CAO | Jan. 26, 2010 D | 183,491 | 0 | 0 | $0 |
| Gregory L Summe | Exe. Chairman of the Board | Feb. 27, 2009 S | 231,724 | 0 | 0 | $0 |
| Michael Louis Battles | VP & Chief Accounting Officer | Feb. 3, 2009 A | 33,750 | 0 | 0 | $0 |
| Katherine A Ohara | SVP, Gen. Counsel, & Secretary | Jan. 29, 2008 A | 65,886 | 0 | 0 | $0 |
| Peter B Coggins | Sr. Vice President | Oct. 28, 2005 M | 87,070 | 0 | 0 | $0 |
| Robert A Barrett | Sr. Vice President | March 3, 2004 M | 2,333 | 0 | 0 | $0 |
| Terrance L Carlson | Sr. VP & General Counsel | Jan. 27, 2004 J | 2,759 | 0 | 0 | $0 |
| Alexis P. Michas | Director | Aug. 25, 2026 G | 6,985 | 0 | 0 | $0 |
| Michelle Mcmurry-Heath | Director | May 7, 2026 A | 6,513 | 0 | 1 | $-58,356 |
| Michael A Klobuchar | Director | May 7, 2026 A | 7,368 | 0 | 0 | $0 |
| Pascale Witz | Director | May 7, 2026 A | 15,985 | 0 | 0 | $0 |
| Samuel R. Chapin | Director | May 7, 2026 A | 22,676 | 0 | 0 | $0 |
| Michel Vounatsos | Director | May 7, 2026 A | 13,977 | 0 | 0 | $0 |
| Frank Witney | Director | May 7, 2026 A | 23,354 | 0 | 0 | $0 |
| Sophie V. Vandebroek | Director | May 7, 2026 A | 7,368 | 0 | 0 | $0 |
| Peter Barrett | Director | May 7, 2026 A | 28,293 | 0 | 0 | $0 |
| Sylvie Gregoire | Director | May 15, 2023 A | 20,482 | 0 | 0 | $0 |
| SULLIVAN PATRICK J | Director | April 30, 2019 A | 30,580 | 0 | 0 | $0 |
| Nicholas A Lopardo | Director | Feb. 5, 2019 S | 39,635 | 0 | 0 | $0 |
| Vicki L Sato | Director | Feb. 9, 2017 M | 29,970 | 0 | 0 | $0 |
| Kenton J Sicchitano | Director | Aug. 24, 2016 M | 27,971 | 0 | 0 | $0 |
| MULLEN JAMES C | Director | Nov. 14, 2014 M | 45,551 | 0 | 0 | $0 |
| Gabriel Schmergel | Director | Feb. 16, 2012 M | 48,012 | 0 | 0 | $0 |
| Robert G Tod | Director | Feb. 14, 2012 M | 42,824 | 0 | 0 | $0 |
| Tamara J Erickson | Director | Feb. 14, 2007 S | 15,352 | 0 | 0 | $0 |
| Prahlad R. Singh | · | Aug. 13, 2026 G | 59,650 | 0 | 5 | $-2,557,859 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 96 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| RSPH · Invesco Exchange-Traded Fund Trust | 2.02% | 115,244 SH | Oct. 1, 2026 | Daily |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.13% | 6,936 NS | July 31, 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 0.98% | 8,002 NS | July 31, 2026 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 0.87% | 53,854 SH | Oct. 1, 2026 | Daily |
| HIBL · Direxion Shares ETF Trust | 0.66% | 4,421 NS | July 31, 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0.50% | 14,749 NS | July 31, 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0.43% | 313,113 NS | July 31, 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0.43% | 39,813 NS | July 31, 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0.36% | 14,789 NS | July 31, 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0.35% | 444,437 NS | July 31, 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0.34% | 37,032 SH | Oct. 1, 2026 | Daily |
| BKMC · BNY Mellon ETF Trust | 0.32% | 18,499 NS | July 31, 2026 | N-PORT |
| ESML · iShares Trust | 0.29% | 66,388 SH | Sept. 11, 2026 | Daily |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0.27% | 49,018 NS | July 31, 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0.26% | 1,624,934 SH | Aug. 19, 2026 | Daily |
| RSP · Invesco Exchange-Traded Fund Trust | 0.25% | 1,580,743 SH | Oct. 1, 2026 | Daily |
| IYH · iShares Trust | 0.22% | 65,502 SH | Sept. 11, 2026 | Daily |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.21% | 8,343 NS | July 31, 2026 | N-PORT |
| SMMD · iShares Trust | 0.19% | 59,552 SH | Sept. 11, 2026 | Daily |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0.18% | 5,732,000 | Oct. 1, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.18% | 53,129 NS | July 31, 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.18% | 335,880 SH | Aug. 19, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.18% | 241,849 NS | July 31, 2026 | N-PORT |
| ISCG · iShares Trust | 0.18% | 13,989 SH | Sept. 11, 2026 | Daily |
| IXJ · iShares Trust | 0.17% | 58,518 SH | Sept. 11, 2026 | Daily |
| REVS · Columbia ETF Trust I | 0.17% | 4,910 NS | July 31, 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0.15% | 2,559,509 SH | Aug. 19, 2026 | Daily |
| CURE · Direxion Shares ETF Trust | 0.14% | 2,195 NS | July 31, 2026 | N-PORT |
| IWS · iShares Trust | 0.13% | 167,213 SH | Sept. 11, 2026 | Daily |
| WSML · iShares Trust | 0.13% | 7,071 SH | Sept. 11, 2026 | Daily |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.12% | 6,239 SH | Oct. 1, 2026 | Daily |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0.12% | 8,519 NS | July 31, 2026 | N-PORT |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0.11% | 4,047,000 | Oct. 1, 2026 | Daily |
| RECS · Columbia ETF Trust I | 0.11% | 55,761 NS | July 31, 2026 | N-PORT |
| PEXL · Pacer Funds Trust | 0.10% | 460 NS | July 31, 2026 | N-PORT |
| IWR · iShares Trust | 0.10% | 456,822 SH | Sept. 11, 2026 | Daily |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0.08% | 113,000 | Oct. 1, 2026 | Daily |
| XT · iShares Trust | 0.08% | 25,072 SH | Sept. 11, 2026 | Daily |
| XOEF · iShares Trust | 0.08% | 142 SH | Sept. 11, 2026 | Daily |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.08% | 9,258 NS | July 31, 2026 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.07% | 4,175 SH | Oct. 1, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.06% | 238,422 NS | July 31, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.05% | 2,685 NS | July 31, 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.05% | 33,073 SH | Oct. 1, 2026 | Daily |
| DFSU · Dimensional ETF Trust | 0.05% | 10,422 NS | July 31, 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.05% | 65,386 NS | July 31, 2026 | N-PORT |
| IVE · iShares Trust | 0.05% | 185,121 SH | Sept. 11, 2026 | Daily |
| IUSV · iShares Trust | 0.04% | 98,188 SH | Sept. 11, 2026 | Daily |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.04% | 25,806 SH | Aug. 19, 2026 | Daily |
| DSI · iShares Trust | 0.04% | 17,178 SH | Sept. 11, 2026 | Daily |
| DCOR · Dimensional ETF Trust | 0.04% | 11,339 NS | July 31, 2026 | N-PORT |
| CHRI · Global X Funds | 0.04% | 27 NS | July 31, 2026 | N-PORT |
| IWD · iShares Trust | 0.04% | 247,738 SH | Sept. 11, 2026 | Daily |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.03% | 3,353 SH | Oct. 1, 2026 | Daily |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.03% | 67,429 SH | Aug. 19, 2026 | Daily |
| TOPC · iShares Trust | 0.03% | 72 SH | Sept. 11, 2026 | Daily |
| PBP · Invesco Exchange-Traded Fund Trust | 0.03% | 660 SH | Oct. 1, 2026 | Daily |
| TILT · FlexShares Trust | 0.02% | 4,536 NS | July 31, 2026 | N-PORT |
| XVV · iShares Trust | 0.02% | 1,280 SH | Sept. 11, 2026 | Daily |
| DFAU · Dimensional ETF Trust | 0.02% | 24,920 NS | July 31, 2026 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0.02% | 89 SH | Sept. 30, 2026 | Daily |
| XYLG · Global X Funds | 0.02% | 120 NS | July 31, 2026 | N-PORT |
| IVV · iShares Trust | 0.02% | 1,406,050 SH | Sept. 11, 2026 | Daily |
| XYLD · Global X Funds | 0.02% | 5,804 NS | July 31, 2026 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0.02% | 2,897,314 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.02% | 3,545,801 SH | Aug. 19, 2026 | Daily |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.02% | 18,403 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.02% | 9,418 SH | Aug. 19, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.02% | 25,220 SH | Aug. 19, 2026 | Daily |
| IYY · iShares Trust | 0.02% | 4,913 SH | Sept. 11, 2026 | Daily |
| PTLC · Pacer Funds Trust | 0.02% | 5,733 NS | July 31, 2026 | N-PORT |
| IWB · iShares Trust | 0.02% | 77,050 SH | Sept. 11, 2026 | Daily |
| XCLR · Global X Funds | 0.02% | 6 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.02% | 147,486 SH | Sept. 11, 2026 | Daily |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.02% | 11,723 SH | Oct. 1, 2026 | Daily |
| IWV · iShares Trust | 0.02% | 30,674 SH | Sept. 11, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.02% | 33,978 NS | July 31, 2026 | N-PORT |
| XRMI · Global X Funds | 0.02% | 81 NS | July 31, 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0.02% | 421 NS | July 31, 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0.02% | 2,684 NS | July 31, 2026 | N-PORT |
| XTR · Global X Funds | 0.02% | 7 NS | July 31, 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0.02% | 779 NS | July 31, 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0.01% | 8,723 NS | July 31, 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.01% | 3,445 SH | Oct. 1, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 98,929 SH | Aug. 19, 2026 | Daily |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BND · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | July 14, 2026 | Daily |
| ISCB · iShares Trust | · | 5,032 SH | Sept. 11, 2026 | Daily |
| ISCV · iShares Trust | · | 15,028 SH | Sept. 11, 2026 | Daily |
RVTY Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
16 analysts · 2026-09-28Mean target $129.00 -14.9%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | · |
| WAT | $22.62B | 35.3 | 7.0% | 20.3% | 27.2% | · |
| IQV | $38.23B | 28.8 | 5.9% | 8.3% | 21.6% | · |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TXG | $2.08B | -46.6 | 5.2% | -6.8% | -5.5% | 69.0% |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.